Role of Ia-like products of the main histocompatibility complex in conditioning skin allograft survival in man

The Journal of Clinical Investigation
J DaussetF T Rapaport

Abstract

This report correlates the survival time of 93 intrafamilial skin allografts performed under conditions of main histocompatibility complex (HLA) haploidentity with donor-recipient compatibility for products of the HLA-A, -B, -C, and -DR, as well as C3 proactivator, Glyoxalase I, and P loci located on the human 6th chromosome. Incompatibilities for HLA-A and -B (and to a lesser extent for HLA-C) and(or) for HLA-DR products exerted a strong influence upon the fate of skin allografts. When HLA-A and -B were considered alone, the most compatible group of grafts had a mean survival time of 15.8 d, as compared with 11.3 d for the most incompatible transplants. HLA-DR compatibility alone was associated with a mean survival time of 15.3 d, whereas HLA-DR-incompatible grafts had a mean survival time of 11.5 d. Incompatibilities for C3 proactivator, Glyoxalase I, and P did not have a significant effect upon graft survival. There was no evidence of an association between donor-recipient incompatibility at HLA-A, -B, or -C or at HLA-DR; such incompatibilities occurred independently of each other, in spite of the state of linkage disequilibrium known to exist between HLA-B and -DR. Incompatibilities for HLA-A, -B, and for HLA-DR exerted a p...Continue Reading

References

Feb 1, 1978·European Journal of Immunology·D FradeliziM Sasportes
Feb 1, 1976·The Journal of Experimental Medicine·J P SoulillouT B Strom
Apr 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·T MeoR Ceppellini
Aug 5, 1976·The New England Journal of Medicine·R B EttengerR N Fine
Jan 1, 1972·The Journal of Experimental Medicine·C A AlperL Watson
Feb 5, 1966·Lancet·D B AmosC M Zmijewski
Dec 1, 1971·Proceedings of the National Academy of Sciences of the United States of America·E J Yunis, D B Amos
Jan 1, 1974·Annual Review of Genetics·J Klein
Dec 1, 1962·The Journal of Clinical Investigation·F T RAPAPORTJ H MULHOLLAND

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.